Translational study searching for synergy between glycopyrronium and indacaterol

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 12, Issue 2, 2015, Pages 175-181

  Cazzola, Mario ^a   Calzetta, Luigino ^b   Segreti, Andrea ^a   Facciolo, Francesco ^c   Rogliani, Paola ^a   Matera, Maria Gabriella ^d  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Combination therapy; Glycopyrronium; Indacaterol; Synergy; Traslational evaluation

Indexed keywords

GLYCOPYRRONIUM BROMIDE; INDACATEROL; SALBUTAMOL; BRONCHODILATING AGENT; INDAN DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; AGED; ARTICLE; ASSESSMENT OF HUMANS; BLISS INDEPENDENCE CRITERION; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; EX VIVO STUDY; FEMALE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TRANSLATIONAL RESEARCH; BRONCHUS; COMBINATION DRUG THERAPY; DOSE RESPONSE; DRUG EFFECTS; DRUG POTENTIATION; FORCED EXPIRATORY VOLUME; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, INHALATION; AGED; AGED, 80 AND OVER; BRONCHI; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; FORCED EXPIRATORY VOLUME; GLYCOPYRROLATE; HUMANS; INDANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; SINGLE-BLIND METHOD; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT OUTCOME;

EID: 84928945280     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2014.922172     Document Type: Article

References (38)

1. National Institute for Health and Clinical Excellence. CG101 Chronic Obstructive Pulmonary Disease (update): full guideline 23 June 2010. Available from: http://www.nice.org. (Last accessed September 26, 2013).
2. Miravitlles M, Soler-Cataluna JJ, Calle M, et al. Spanish COPD Guidelines (GesEPOC). Pharmacological treatment of stable COPD. Arch Bronconeumol 2012;48:247-257.
3. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Th oracic Society, and European Respiratory Society. Ann Intern Med 2011;155:179-191.
4. Global initiative for chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Revised 2013. Available from: http://www.goldcopd.org/(Last accessed September 26, 2013).
5. van der Molen T, Cazzola M. Beyond lung function in COPD management: eff ectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J 2012;21:101-108.
6. Cazzola M, Molimard M. Th e scientifi c rationale for combining long-acting 2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Th er 2010;23:257-267.
7. Meurs H, Dekkers BG, Maarsingh H, et al. Muscarinic receptors on airway mesenchymal cells: novel fi ndings for an ancient target. Pulm Pharmacol Th er 2013;26:145-155.
8. Dahl R, Chapman KR, Rudolf M, et al. Safety and effi cacy of dual bronchodilation with QVA149 in COPD patients: Th e ENLIGHTEN study. Respir Med 2013;107:1558-1567.
9. Istituto Nazionale dei Tumori-Independent Ethics Committee: From the biobank to the research biorepository: ethical and legal recommendations, Milan, Italy. Available from: http://www.progettorol.it/doc/OECI-BIOBANKS- Oct.2010.pdf. 2010. (Last accessed September 26, 2013).
10. CNBBSV. Raccolta di campioni biologici a fi ni di ricerca: consenso informato. Available from: http://www.governo. it/bioetica/gruppo-misto/Consenso-Informato-allegato- Petrini-2009.pdf. 2009 (Last accessed September 26, 2013).
11. Freas W, Hart JL, Golightly D, et al. Contractile properties of isolated vascular smooth muscle after photoradiation. Am J Physiol 1989: 256:H655-664.
12. Hatake K, Wakabayashi I. Ethanol suppresses L-arginineinduced relaxation response of rat aorta stimulated with bacterial lipopolysaccharide. Nihon Arukoru Yakubutsu Igakkai Zasshi 2000: 35:61-68.
13. Bleecker ER. Cholinergic and neurogenic mechanisms in obstructive airways disease. Am J Med 1986;8:93-102.
14. Goldoni M, Johansson C. A mathematical approach to study combined eff ects of toxicants in vitro: evaluation of the Bliss independence criterion and the Loewe additivity model. Toxicol In Vitro 2007;21:759-769.
15. Lee SI. Drug interaction: focusing on response surface models. Kor J Anesthesiol 2010;58:421-434.
16. Boik JC, Newman RA, Boik RJ. Quantifying synergism/antagonism using nonlinear mixed-eff ects modeling: a simulation study. Stat Med 2008;27:1040-1061.
17. Greco WR, Bravo G, Parsons JC. Th e search for synergy: a critical review from a response surface perspective. Pharmacol Rev 1995;47(2): 331-385.
18. Tallarida RJ. Drug synergism: its detection and applications. J Pharmacol Exp Th er 2001;298(3):865-872.
19. Goodman LS, Gilman A, Brunton LL. Goodman &Gilman's Manual of Pharmacology and Th erapeutics. New York: McGraw-Hill Medical, 2011.
20. Motulsky H, Christopoulos A. Fitting models to biological data using linear and nonlinear regression : a practical guide to curve fi tting. Oxford, UK: Oxford University Press, 2004.
21. Goodman LS GA, Brunton LL. Goodman &Gilman's Manual of Pharmacology and Th erapeutics. New York: McGraw-Hill Medical, 2008.
22. Rogliani P, Calzetta L, Rendina EA, et al. Th e infl uence of propofol, remifentanil and lidocaine on the tone of human bronchial smooth muscle. Pulm Pharmacol Th er 2013;26:325-331.
23. Motulsky H. Intuitive Biostatistics. New York: Oxford University Press, 1995.
24. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-946.
25. GINA. Global Initiative for Asthma. Guidelines: Global Strategy for Asthma Management And Prevention (GINA). 2011. Available from: http://www.ginasthma.com/. (Last accessed September 26, 2013).
26. La Piana GE, Corda L, Bertella E, et al. Dose-response curve to salbutamol during acute and chronic treatment with formoterol in COPD. Int J Chron Obstruct Pulmon Dis 2011;6:399-405.
27. Campbell IA, Middleton WG, McHardy GJ, et al. Interaction between isoprenaline and aminophylline in asthma. Th orax 1977;32:424-428.
28. Snyder S, D'Argenio DZ, Weislow O, et al. Th e triple combination indinavir-zidovudine-lamivudine is highly synergistic. Antimicrob Agents Chemother 2000;44:1051-1058.
29. Novartis Global. Novartis fi rst-in-class once-daily dual bronchodilator Ultibro Breezhaler (QVA149) achieves near simultaneous approval for COPD patients in Europe and Japan. Available from: http://www.novartis.com/newsroom/media-releases/en/2013/1730580.shtml (Last accessed September 29, 2013).
30. Kume H, Imbe S, Iwanaga T, et al. Involvement of the BK channels/G proteins processes in the synergistic eff ects between anticholinergic agents and beta2-adrenoceptor agonists in airway smooth muscle (abstract 3032). (Presented at the European Respiratory Society Annual Congress, Barcelona, Spain, September 7-11, 2013).
31. Bouyssou T, Casarosa P, Pieper M, et al. Synergistic bronchoprotective activity of the long-acting beta 2-agonist olodaterol with tiotropium (long-acting M3 antagonist) and ciclesonide (inhaled steroid) on the ovalbumin-induced bronchoconstriction in anaesthetized guinea pigs (abstract 3451). Eur Respir J 2011;38(Suppl 55):613s.
32. Bouyssou T, Schnapp A, Casarosa P, Pieper MP. Addition of the new once-daily LABA BI 1744 to tiotropium results in superior bronchoprotection in pre-clinical models (abstract A4445). Am J Respir Crit Care Med 2010;181:A4445.
33. Matera MG, Cazzola M, Vinciguerra A, et al. A comparison of the bronchodilating eff ects of salmeterol, salbutamol and Ipratropium bromide in patients with chronic obstructive pulmonary disease. Pulm Pharmacol 1995;8:267-271.
34. Verkindre C, Fukuchi Y, Flémale, A et al. Sustained 24-h effi cacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Respir Med 2010;104:1482-1489.
35. Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 2013;42:1484-1494.
36. Troosters T, Celli B, Lystig T, et al. Tiotropium as a fi rst maintenance drug in COPD: secondary analysis of the UPLIFT trial. Eur Respir J 2010;36:65-73.
37. Hansen G, Andrew M, Bjermer L, et al. Retningslinjer fur utredning og behandling av kronisk obstruktiv lungesykdom. Tidsskr Nor Laegeforen1995;115:710-713.
38. Barclay J, Whiting B, Addis GJ. Th e infl uence of theophylline on maximal response to salbutamol in severe chronic obstructive pulmonary disease. Eur J Clin Pharmacol 1982;22:389-393.